Rein Therapeutics (NASDAQ:RNTX) Cut to “Hold” at Brookline Capital Management

Brookline Capital Management downgraded shares of Rein Therapeutics (NASDAQ:RNTX) from a buy rating to a hold rating in a research report report published on Wednesday morning, MarketBeat.com reports.

A number of other research analysts have also weighed in on RNTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a research note on Wednesday. Finally, Loop Capital set a $6.00 price objective on shares of Rein Therapeutics in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Price Performance

Shares of NASDAQ RNTX opened at $1.37 on Wednesday. Rein Therapeutics has a 1 year low of $1.02 and a 1 year high of $3.50. The company’s 50-day moving average is $1.32 and its 200 day moving average is $1.31. The stock has a market capitalization of $36.02 million, a P/E ratio of -0.52 and a beta of 1.31.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Research analysts anticipate that Rein Therapeutics will post -1.56 earnings per share for the current year.

Insider Activity at Rein Therapeutics

In other news, major shareholder Voss Capital, Lp bought 104,183 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were bought at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the purchase, the insider owned 926,441 shares in the company, valued at $1,130,258.02. This represents a 12.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have acquired 380,057 shares of company stock worth $508,618. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Rein Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Gleason Group Inc. purchased a new position in shares of Rein Therapeutics in the third quarter valued at about $26,000. Blair William & Co. IL bought a new stake in Rein Therapeutics during the 2nd quarter valued at approximately $33,000. Meridian Wealth Advisors LLC bought a new stake in Rein Therapeutics during the 2nd quarter valued at approximately $40,000. Exencial Wealth Advisors LLC purchased a new position in Rein Therapeutics in the 2nd quarter worth approximately $43,000. Finally, Susquehanna International Group LLP bought a new position in Rein Therapeutics in the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.